M
Mareike Verbeek
Researcher at Technische Universität München
Publications - 55
Citations - 1409
Mareike Verbeek is an academic researcher from Technische Universität München. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 11, co-authored 36 publications receiving 1024 citations.
Papers
More filters
Journal ArticleDOI
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Robert Zeiser,Andreas Burchert,Claudia Lengerke,Mareike Verbeek,Kristina Maas-Bauer,S K Metzelder,Silvia Spoerl,Markus Ditschkowski,Matyas Ecsedi,Katja Sockel,Francis Ayuk,Salem Ajib,F.S. de Fontbrune,Il-Kang Na,Livius Penter,Udo Holtick,Dominik Wolf,Esther Schuler,Everett Meyer,Petya Apostolova,Hartmut Bertz,Reinhard Marks,Michael Lübbert,Ralph Wäsch,Christoph Scheid,Friedrich Stölzel,Rainer Ordemann,Gesine Bug,Guido Kobbe,Robert S. Negrin,Mats Brune,Alexandros Spyridonidis,Annette Schmitt-Gräff,W.J.F.M. van der Velden,Gerwin Huls,Stephan Mielke,G. U. Grigoleit,Jürgen Kuball,Ryan Flynn,Gabriele Ihorst,Jing Du,Bruce R. Blazar,Renate Arnold,Kröger N,Jakob Passweg,Jörg Halter,Gérard Socié,Dietrich W. Beelen,Christian Peschel,Andreas Neubauer,Jürgen Finke,Justus Duyster,N von Bubnoff +52 more
TL;DR: Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.
Journal ArticleDOI
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
Silvia Spoerl,Nimitha R. Mathew,Michael Bscheider,Annette Schmitt-Graeff,Sophia Chen,Tony A. Mueller,Mareike Verbeek,Julius C. Fischer,Vera Otten,Martina Schmickl,Kristina Maas-Bauer,Jürgen Finke,Christian Peschel,Justus Duyster,Hendrik Poeck,Robert Zeiser,Nikolas von Bubnoff +16 more
TL;DR: Ruxolitinib represents a novel targeted approach in GVHD by suppression of proinflammatory signaling that mediates tissue damage and by promotion of tolerogenic Treg cells.
Journal ArticleDOI
Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT
Michael Neuenhahn,Julia Albrecht,Marcus Odendahl,Fabian Schlott,Georg Dössinger,Matthias Schiemann,S Lakshmipathi,Klaus Martin,Donald Bunjes,Stephanie von Harsdorf,Eva M. Weissinger,Helge Dr Menzel,Mareike Verbeek,Lutz Uharek,Nicolaus Kröger,Eva-Maria Wagner,Guido Kobbe,Tobias Schroeder,Michael Schmitt,Gerhard Held,W. Herr,Lothar Germeroth,Halvard Bonig,Torsten Tonn,Torsten Tonn,Hermann Einsele,Dirk H. Busch,Götz Ulrich Grigoleit +27 more
TL;DR: In summary, adoptive transfer correlated with functional virus-specific T-cell reconstitution in D+ depl patients, and suboptimal HLA match may counteract expansion of TPD-derived virus- specific T cells in D− patients.
Journal ArticleDOI
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
Dietrich W. Beelen,Rudolf Trenschel,Matthias Stelljes,Christoph Groth,Tamás Masszi,Péter Reményi,Eva Maria Wagner-Drouet,Beate Hauptrock,Peter Dreger,Thomas Luft,Wolfgang Bethge,Wichard Vogel,Fabio Ciceri,Jacopo Peccatori,Friedrich Stölzel,Johannes Schetelig,Christian Junghanß,Christina Grosse-Thie,Mauricette Michallet,Hélène Labussière-Wallet,Kerstin Schaefer-Eckart,Sabine Dressler,Goetz Ulrich Grigoleit,Stephan Mielke,Christof Scheid,Udo Holtick,Francesca Patriarca,Marta Medeot,Alessandro Rambaldi,Maria Caterina Micò,Dietger Niederwieser,Georg Nikolaus Franke,Inken Hilgendorf,Nils Rudolf Winkelmann,Domenico Russo,Gérard Socié,Régis Peffault de Latour,Ernst Holler,Daniel Wolff,Bertram Glass,Jochen Casper,Gerald Wulf,Helge Menzel,Nadezda Basara,Maria Bieniaszewska,Gernot Stuhler,Mareike Verbeek,Sandra Grass,Anna Paola Iori,Juergen Finke,Fabio Benedetti,Uwe Pichlmeier,Claudia Hemmelmann,Michael Tribanek,Anja Klein,Heidrun A. Mylius,Joachim Baumgart,Monika Dzierzak-Mietla,Miroslaw Markiewicz,Miroslaw Markiewicz +59 more
TL;DR: Treosulfan was non-inferior to busulfan when used in combination with fludarabine as a conditioning regimen for allogeneic HSCT and safety in all patients who received treatment was assessed.
Journal ArticleDOI
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD + AML but retains in vitro sensitivity to PKC412 and Sunitinib
Corinna Albers,Hannes Leischner,Mareike Verbeek,C Yu,A L Illert,Christian Peschel,N von Bubnoff,Justus Duyster +7 more
TL;DR: The secondary FLT 3-ITD F691L mutation induces resistance to AC220 in FLT3- ITD + AML but retains in vitro sensitivity to PKC412 and Sunitinib.